Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin
Publication Type:
Journal Article
Authors:
Manns, M.P.;
Pockros, P.J.;
Norkrans, G.;
Smith, C.I.;
Morgan, T.R.;
Haussinger, D.;
Shiffman, M.L.;
Hadziyannis, S.J.;
Schmidt, W.N.;
Ira M. Jacobson;
Barcena, R.;
E R Schiff;
Shaikh, O.S.;
Bacon, B.;
P. Marcellin;
Deng, W.;
Esteban-Mur, R.;
Poynard, T.;
Pedicone, L.D.;
Brass, C.A.;
Albrecht, J.K.;
Gordon, S.C.Source:
J Viral Hepat, Volume 20, Issue 8, p.524-529 (2013)
Keywords:
blood,
clinical trial,
drug therapy,
Drug Therapy,Combination,
Follow-Up Studies,
Germany,
HCV,
Hepacivirus,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hepatitis C,Chronic,
Humans,
interferon,
Interferon Alfa-2b,
Interferon-alpha,
isolation & purification,
Multicenter Studies,
Patients,
peginterferon,
peginterferon alfa-2b,
Polyethylene Glycols,
Prospective Studies,
Proteins,
Recombinant Proteins,
Recurrence,
Research,
Research Support,
Ribavirin,
Rna,
Rna,Viral,
Serum,
sustained virologic response,
SVR,
therapeutic use,
therapy,
treatment,
Treatment Outcome
